Adalimumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
Abemaciclib
Selective CDK4/6 inhibitor (antineoplastic) · Antineoplastic
START
150 mg PO twice daily (with endocrine therapy)
TYPICAL MAX
300 mg/day (150 mg once daily in severe hepatic)
STOP IF
Severe diarrhoea unresponsive, ILD/pneumonitis, or grade 3 hepatotoxicity
WATCH
CBC at baseline/q2w ×2 cycles then monthly, LFTs, diarrhoea management, VTE
CDSCO approvedSchedule HATC L01EF03
KDIGO 2024 + manufacturer label
- ONSET
- 2h · absorption
- PEAK
- 8h · Tmax
- t½
- 1d · t½
- DURATION
- 12h · twice-daily
EXCRETION
~81% faecal; ~3% renal
route + CYP
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
Can cause fetal harm — avoid; effective contraception during and 3 weeks after.
FDA category + note
Top interactionssee all 12 →
- AdalimumabSevereDatabaseDDInter
- ApalutamideSevereDatabaseDDInter
- AtazanavirSevereDatabaseDDInter
- BaricitinibSevereDatabaseDDInter
Mechanism
Selective ATP-competitive inhibitor of cyclin-dependent kinases 4 and 6, blocking Rb phosphorylation and arresting hormone-receptor-positive breast cancer cells in G1; continuous dosing distinguishes it from palbociclib/ribociclib.
Indications
HR-positive HER2-negative advanced breast cancer (with endocrine therapy)Adjuvant therapy of node-positive HR-positive HER2-negative early breast cancer (with endocrine therapy)
Dosing
- Adult
- Advanced: 150 mg PO twice daily with endocrine therapy. Early-disease adjuvant: 150 mg PO twice daily for 2 years.
- Pediatric
- Not established.
- Renal adjustment
- No adjustment for CrCl ≥30; severe (CrCl <30) not studied.
- Hepatic adjustment
- Severe (Child-Pugh C): reduce to 150 mg once daily.
- Geriatric
- No specific adjustment.
- Max dose
- 300 mg/day (150 mg twice daily)
Pharmacokinetics
Onset
Tumour effect over weeks
Peak effect
~8 h (Tmax)
Duration
~12 h (twice-daily)
Half-life
~18–38 h (active metabolites)
Bioavailability
~45%; food does not significantly affect
Protein binding
~95%
Metabolism
Hepatic CYP3A4 (active M2/M20 metabolites)
Excretion
~81% faecal; ~3% renal
Contraindications
- Severe hypersensitivity
- Caution: pregnancy, significant hepatic impairment, active infection
Side effects
Common
DiarrhoeaFatigueNeutropeniaNauseaAbdominal painAnaemia
Serious
- Severe diarrhoea / dehydration
- Severe neutropenia
- Interstitial lung disease / pneumonitis
- Hepatotoxicity
- Venous thromboembolism
Pregnancy & lactation
Pregnancy
Can cause fetal harm — avoid; effective contraception during and 3 weeks after.
Lactation
Avoid breastfeeding during and 3 weeks after therapy.
Drug interactions
Apalutamide
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Atazanavir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Baricitinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Boceprevir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Carbamazepine
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Ceritinib
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Certolizumab
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cladribine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Clarithromycin
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Clozapine
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Cobicistat
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Related guidelines
Ask House about Abemaciclib
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e, Katzung, BNF·Verified: 2026-05-20 · House clinical team·Cockpit curated: 2026-05-20